Tirzepatide Providers in Kansas

What it is

Tirzepatide is a once-weekly prescription shot made by Eli Lilly. It acts on two gut hormones, GIP and GLP-1, that help control appetite and blood sugar. It's sold under two brand names:

• Zepbound is approved for weight loss and keeping weight off. It's also approved to treat moderate to severe obstructive sleep apnea in adults with obesity [1].
• Mounjaro is approved for adults with type 2 diabetes [3].

Zepbound comes as a single-dose pen, a vial or a multi-dose KwikPen that holds 4 weekly doses. You start at 2.5 mg and go up by 2.5 mg at least every 4 weeks, to a maintenance dose of 5, 10 or 15 mg [1]. The label has a boxed warning about thyroid tumors seen in animal studies [1].

Who it's for

Zepbound is for adults with obesity, or with overweight plus at least one weight-related health problem, such as high blood pressure or high cholesterol. It's also for adults with obesity who have moderate to severe sleep apnea [1].

It's used along with a lower-calorie diet and more activity. Most people stay on it long term, because weight often returns after stopping.

Mounjaro is for adults with type 2 diabetes. If you have diabetes, your doctor will usually start there, since diabetes coverage is easier to get.

Tirzepatide isn't right for everyone. Tell your provider if you or a family member has had medullary thyroid cancer or MEN 2, or if you've had pancreatitis [1]. It isn't approved for people under 18 [1].

Cost and coverage

Commercial insurance. If your plan covers Zepbound pens, the savings card can bring your cost to as little as $25 a fill. It pays up to $100 a month and $1,300 a year [2]. Mounjaro's card works the same way, paying up to $150 a month for covered patients [3]. Both cards end December 31, 2026 [2][3].

Self-pay. Lilly sells the Zepbound KwikPen and vials for $299 a month at 2.5 mg and $399 at 5 mg. Higher doses are $449 a month if you refill within 45 days. If you wait longer, the price goes up to $499 for 7.5 mg and $699 for 10 to 15 mg [2].

Medicare. From July 1, 2026, through December 31, 2027, the Medicare GLP-1 Bridge covers the Zepbound KwikPen for $50 a month. Single-dose pens and vials aren't included. You need Part D coverage, prior approval and a qualifying BMI. If you have type 2 diabetes or moderate to severe sleep apnea, you're not eligible for the Bridge, but your Part D plan may cover tirzepatide [4].

Medicaid. States must cover these drugs for diabetes but can choose whether to cover them for weight loss [5].

For more, see our Zepbound savings guide, how Zepbound works and GLP-1 guides.

How to choose a provider

Look for real medical care. A good provider reviews your health history, orders lab work when needed and checks in as your dose goes up. Ask who handles side effects like nausea, and how often you'll be seen.

Ask what they prescribe. Ask if they prescribe brand-name Zepbound or Mounjaro. Some businesses sell compounded "tirzepatide" instead. Compounded drugs are not FDA approved, and FDA has had reports of people hurt by dosing mistakes [6]. FDA declared the tirzepatide shortage over in December 2024 [7]. Our list doesn't include businesses that market compounded GLP-1s.

Ask about the paperwork. Ask if they'll handle prior approval with your insurer. If you have sleep apnea, ask whether they can document it. That's a separate approved use that some plans cover.

Confirm the basics yourself. Call to check insurance, new-patient openings and telehealth. We don't verify these.